ABSTRACT
Objective:To evaluate the efficacy and safety of SPOT (GI Supply, USA), a new carbon-based permanent marker approved by the Food and Drug Administration (FDA), in the endoscopic marking for gastrointestinal lesions.Methods:A total of 115 patients with gastrointestinal lesions who underwent endoscopic treatment or surgery in Beijing Friendship Hospital or Beijing Chao-Yang Hospital from April 2019 to November 2019 were enrolled in the study. SPOT was used to mark the lesions, and marking points were found during endoscopic treatment or surgery to calculate the effective marking rate by single-group target value method. Adverse events after marking were recorded, and the changes of blood routine test, liver and kidney functions before and after marking were compared.Results:The effective rate of endoscopic marking with SPOT was 99.13% (114/115). The longest marking time was 57 days. There was no puncture of intestinal wall or injection into abdominal cavity during the marking process. One patient developed mild fever after marking. The incidence of adverse events was 23.48% (27/115), which were all unrelated to the test equipment. There was no significant difference in blood routine tests or liver and kidney functions before and after marking ( P>0.05). Conclusion:SPOT produced by GI Supply can effectively mark gastrointestinal lesions without serious adverse events, which meets the requirements of clinical use.
ABSTRACT
Objective:To investigate the clinical, endoscopic and pathological characteristics of early Barrett esophageal adenocarcinoma (BEA) and to evaluate the treatment efficacy of endoscopic submucosal dissection (ESD).Methods:Data of 13 patients who were diagnosed as early BEA and treated by ESD in Beijing Friendship Hospital from November 2015 to June 2018 were retrospectively analyzed, including clinical data, endoscopic manifestations and pathological information.Results:Out of 13 patients, 10 were male. One had underlying long-segment Barrett esophagus (LSBE), 6 had short-segment Barrett esophagus (SSBE), and 6 had super short-segment Barrett esophagus (less than 1 cm). Two arose from circumferential Barrett esophageal (BE) and 11 from tongue-like BE. Ten lesions were located on the right anterior side wall (12-2 o′clock) of the esophagogastric junction (EGJ), and 12 lesions were superficial type (0-Ⅱ). ESD was successfully conducted in all the patients without any complication. The en bloc and curative resection rate was 100% (13/13) and 92% (12/13), respectively. Pathology examination found 9 well-differentiated adenocarcinoma and 10 intramucosal cancer. No recurrence was detected in 11 patients during follow-up of 3.3-29.3 months.Conclusion:Early BEA tends to occur in elderly male, and mostly originated from non-LSBE and tongue-like BE. Most lesions are superficial type and located on the right anterior side wall of EGJ. In pathology, most lesions are well-differentiated adenocarcinoma and limited to the mucosa. ESD is a safe and efficient treatment for BEA.
ABSTRACT
Background: The detection rate of early gastric cancer has been increasing over recent decades, but synchronous multiple early gastric cancer (SMEGC) remains a challenge for endoscopists. It is important to improve the endoscopic diagnosis and treatment of SMEGC. Aims: To investigate the clinicopathological features of SMEGC and the correlation of its major and minor lesions. Methods: The medical records of 231 consecutive early gastric cancer patients treated by endoscopic submucosal dissection (ESD) in Beijing Friendship Hospital from Jun. 2013 to Dec. 2018 were retrospectively analyzed for comparing the clinical, endoscopic, pathological features and treatment outcome between solitary early gastric cancer (SEGC) and SMEGC. The relevance of major and minor lesions of SMEGC in endoscopic and pathological features was also analyzed. Results: Of the 231 early gastric cancer patients, 16 (6.9%) were SMEGC (34 lesions). The gender, age, and family history of GI tumors were comparable between SEGC and SMEGC (P>0.05). Furthermore, lesions of these two groups did not differ in tumor size, vertical location, histological differentiation, depth of invasion, and mucosal background (P>0.05). With respect to horizontal location and macroscopic type, SMEGC lesions were more often located in posterior wall (38.2%) and presented as elevated type (47.1%) as compared with SEGC lesions (P0.05). Conclusions: SMEGC and SEGC have similar clinicopathological features. The major and minor lesions of SMEGC are consistent in characteristics of macroscopic type, histological differentiation, depth of invasion, and mucosal background. ESD is a feasible treatment for SMEGC.